Faculty

Back to Index
Afsaneh Barzi, MD
Assistant Professor of Clinical Medicine
Medical Director
Medicine
NOR 3440 Health Sciences Campus Los Angeles
+1 323 865 3829

Overview

Barzi earned her M.D. from Tehran University of Medical Sciences, then went on to earn a Master’s in Health Informatics and a Doctorate in Public Health Management and Policy Sciences from the University of Texas Health Science Center in Houston. She recently completed a fellowship in hematology and oncology at the Cleveland Clinic’s Taussig Cancer Center.

Her research interests are the development of new cancer therapies as well as healthcare economics and metrics of healthcare quality for improving patient care. Dr. Barzi has proposed a phase II study to investigate the overall survival benefit of adding lapatinib to docetaxel in a second line setting in patients with trastuzumab-resistant, HER2-positive gastric cancer.

“Delivery of personalized treatment to gastric cancer patients has lagged behind other diseases,” Barzi says. “My goal is to establish a second-line treatment for these patients that are HER2-positive and to better understand the mechanisms of resistance to HER2-targeted therapy, paving the way for new therapies that can overcome that resistance.”

Awards

National Cancer Institute: Travel Award for Markers in Cancer, 2013

Southwest Oncology Group: Young Investigator Award, 2011

Publications

Shabihkhani M, Yu SS, Yang D, Lin S, Hamilton AS, Lenz HJ, Barzi A. Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population. Clin Colorectal Cancer. 2016 Dec; 15(4):e221-e227. View in: PubMed

Grubman J, Barzi A. Lost in Translation: The Patient-Physician Relationship in the Molecular Era. J Palliat Med. 2015 Nov; 18(11):987-8. View in: PubMed

Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S, Sunakawa Y, Stremitzer S, Parekh A, Okazaki S, Berger MD, Barzi A, Lenz HJ. Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach. Mol Cancer Ther. 2015 Oct; 14(10):2401-8. View in: PubMed

Grubman J, Barzi A. We Don't Know What We Don't Know About Adolescent and Young Adult Patients with Familial Adenomatous Polyposis-Related Colorectal Cancer. J Adolesc Young Adult Oncol. 2015 Sep 1; 4(3):105-7. View in: PubMed

Semrad T, Barzi A, Lenz HJ, Hutchins IM, Kim EJ, Gong IY, Tanaka M, Beckett L, Holland W, Burich RA, Snyder-Solis L, Mack P, Lara PN. Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. Int J Clin Oncol. 2015 Jun; 20(3):518-24. View in: PubMed

Barzi A, Sadeghi S, Kattan MW, Meropol NJ. Comparative effectiveness of screening strategies for lynch syndrome. J Natl Cancer Inst. 2015 Apr; 107(4). View in: PubMed

Barzi A, Lenz HJ. Cost-effectiveness of genomic testing for colorectal cancer: are we there yet? Oncology (Williston Park). 2015 Mar; 29(3). View in: PubMed

Sunakawa Y, Wakatsuki T, Yang D, Zhang W, Ning Y, Stintzing S, Stremitzer S, Yamauchi S, Sebio A, El-Khoueiry R, Iqbal S, Barzi A, Gerger A, Stotz M, Azuma M, Watanabe M, Koizumi W, Lenz HJ. Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients. Pharmacogenet Genomics. 2014 Dec; 24(12):588-96. View in: PubMed

Wakatsuki T, Stintzing S, Zhang W, Yang D, Azuma M, Ning Y, Yamauchi S, Matsusaka S, Volz NB, Sunakawa Y, Koizumi W, Watanabe M, Barzi A, El Khoueiry AB, Shah MA, Lenz HJ. Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent. Pharmacogenet Genomics. 2014 Nov; 24(11):539-47. View in: PubMed

Barzi A, Thara E. Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment. Expert Opin Biol Ther. 2014 Sep; 14(9):1319-32. View in: PubMed

Yu S, Shabihkhani M, Yang D, Thara E, Senagore A, Lenz HJ, Sadeghi S, Barzi A. Timeliness of Adjuvant Chemotherapy for Stage III Adenocarcinoma of the Colon: A Measure of Quality of Care. Clin Colorectal Cancer. 2013 Dec; 12(4):275-9. View in: PubMed

Barzi A, Lenz AM, Labonte MJ, Lenz HJ. Molecular pathways: estrogen pathway in colorectal cancer. Clin Cancer Res. 2013 Nov 1; 19(21):5842-8. View in: PubMed

Wakatsuki T, LaBonte MJ, Bohanes PO, Zhang W, Yang D, Azuma M, Barzi A, Ning Y, Loupakis F, Saadat S, Volz N, Stintzing S, El-Khoueiry R, Koizumi W, Watanabe M, Shah M, Stebbing J, Giamas G, Lenz HJ. Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States. Mol Cancer Ther. 2013 Oct; 12(10):2261-72. View in: PubMed

Barzi A, Lenz HJ. Angiogenesis-related agents in esophageal cancer. Expert Opin Biol Ther. 2012 Oct; 12(10):1335-45. View in: PubMed

Sadeghi S, Barzi A, Kattan MW, Meropol NJ. Screening for Lynch syndrome in the general population-letter. Cancer Prev Res (Phila). 2011 Mar; 4(3):471; author reply 472. View in: PubMed

Barzi A, Sekeres MA. Myelodysplastic syndromes: a practical approach to diagnosis and treatment. Cleve Clin J Med. 2010 Jan; 77(1):37-44. View in: PubMed

Sadeghi S, Barzi A, Sadeghi N, King B. A Bayesian model for triage decision support. Int J Med Inform. 2006 May; 75(5):403-11. View in: PubMed

Sadeghi S, Barzi A, Smith JW. Ontology Driven Construction of a Knowledgebase for Bayesian Decision Models Based on UMLS. Stud Health Technol Inform. 2005; 116:223-8. View in: PubMed

Barzi A, Sadeghi S, King BR. Self-administered decision support tool for triage: results of a retrospective study. Stud Health Technol Inform. 2002; 85:45-51. View in: PubMed

Powered bySC CTSI